Latest News
Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline
Advance™ technology-enabled solution enables R&D organizations to cut study timelines, deliver cost savings and reduce animal experimentation.
PHILADELPHIA, PA – (BUSINESS WIRE) – January 25, 2024 - Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that its latest in silico solution offering known as Advance™ , is providing clients with a technology-enabled approach for assessing carcinogenicity based on the ICH S1B Weight of Evidence (WoE) Addendum.
Instem Now Part of ARCHIMED to Further Accelerate Growth and Impact
November 27, 2023 - Healthcare investment specialist ARCHIMED has the expertise, experience, enthusiasm and financial strength to fully back Instem’s ambitions.
Instem Announces New Software Solution to Support Updated Nitrosamines Guidance
September 28, 2023 - New Software Module Introduced to Support the Latest Regulatory-approved Carcinogenic Potency Categorization Approach (CPCA)
Instem Announces Transfer of ToxHub Platform and launch of Centrus®
May 15, 2023 - New powerful technology and data sharing suite provides a range of translational science solutions
Instem Unveils New Additions to its Leading Computational Toxicology Software Suite
November 2, 2022 - New functionality along with Enhanced Models to Deliver More Efficient and Comprehensive Predictions in Chemical Safety
Events
Proud to be Sponsoring the British Toxicology Society Annual Congress 2024
April 15 - 17, 2024
Spaces at the Spine, Liverpool
Poster Presentations
Technology-enabled Approval Acceleration: Spotlighting the ICH S1B Weight of Evidence
Frances Hall, PhD, Scientific Application Director
Keeping control: Trends in Virtual Control Groups for Ethical Animal Experimentation
Marc Ellison, Director, SEND Solutions
Solution Areas: In Silico, Preclinical Study Management, SEND